Direct compression (DC) is a very popular and widely used technology in the pharmaceutical sector; it is in fact the least complex and most advantageous process in terms of costs and time compared to other approaches. Thanks to the DC it is possible to mix the active ingredients (API) with the excipients and then proceed to compression, giving life easily to different dosage forms.

However, the direct compression technique and the use of modern machinery require that the excipients and APIs form a compact mixture, characterized by excellent flowability and low propensity for segregation and dispersion of powders.

Among the excipients used by the pharmaceutical industry, lactose is certainly among the most used; however, in cases where compactness and smoothness are not suitable for direct compression, it will be necessary to resort to further processing.

To overcome this technological and manufacturing barrier, Meggle has developed a range of co-processed, effective and efficient alternatives to more traditional granulation techniques.

• Cellactose® 80: spray-dryed co-processed excipient; it consists of lactose and cellulose. Excellent binding and filling properties
• Microcelac® 100: consisting of 75% alpha-lactose monohydrate and 25% microcrystalline cellulose (MCC). Excellent for direct compression thanks to its excellent smoothness and compacting capacity.
• Combilac®: highly functional monodisperse combination of three elements: alpha-lactose monohydrate, MCC and starch
• Retalac®: 1:1 mixture of HPMC and lactose alpha monohydrate. Dedicated to direct compression for sustained release formulations
• Starlac®: composed of 85% alpha-lactose monohydrate and 15% native corn starch. The perfect combination of excellent smoothness and exceptional disintegrating properties

Meggle co-processed products are distributed in Italy by Faravelli Pharma Division.